4.0 Article

The Associations of Insomnia With Costly Workplace Accidents and Errors Results From the America Insomnia Survey

期刊

ARCHIVES OF GENERAL PSYCHIATRY
卷 69, 期 10, 页码 1054-1063

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2011.2188

关键词

-

资金

  1. Actelion
  2. Affectis
  3. Astra-Zeneca
  4. Brain-Lab
  5. Daimler Benz
  6. Essex
  7. GlaxoSmithKline
  8. Lundbeck
  9. Neurim
  10. NeuroBiotec
  11. Neurocrine
  12. Novartis
  13. Organon
  14. Sanofi
  15. Schwarz
  16. Sepracor
  17. Takeda
  18. UCB
  19. Volkswagen
  20. Weinmann
  21. Wyeth
  22. Aventis
  23. Cephalon
  24. Pfizer
  25. SchoeringPlough
  26. Somaxon
  27. Somnus
  28. Syrex
  29. TransOral
  30. Ventus
  31. Xenoport
  32. Merck Co.
  33. Merck Co

向作者/读者索取更多资源

Context: Insomnia is a common and seriously impairing condition that often goes unrecognized. Objectives: To examine associations of broadly defined insomnia (ie, meeting inclusion criteria for a diagnosis from International Statistical Classification of Diseases, 10th Revision, DSM-IV, or Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition) with costly workplace accidents and errors after excluding other chronic conditions among workers in the America Insomnia Survey (AIS). Design/Setting: A national cross-sectional telephone survey (65.0% cooperation rate) of commercially insured health plan members selected from the more than 34 million in the HealthCore Integrated Research Database. Participants: Four thousand nine hundred ninetyone employed AIS respondents. Main Outcome Measures: Costly workplace accidents or errors in the 12 months before the AIS interview were assessed with one question about workplace accidents that either caused damage or work disruption with a value of $500 or more and another about other mistakes that cost your company $500 or more. Results: Current insomnia with duration of at least 12 months was assessed with the Brief Insomnia Questionnaire, a validated (area under the receiver operating characteristic curve, 0.86 compared with diagnoses based on blinded clinical reappraisal interviews), fully structured diagnostic interview. Eighteen other chronic conditions were assessed with medical/pharmacy claims records and validated self-report scales. Insomnia had a significant odds ratio with workplace accidents and/or errors controlled for other chronic conditions (1.4). The odds ratio did not vary significantly with respondent age, sex, educational level, or comorbidity. The average costs of insomnia-related accidents and errors ($32062) were significantly higher than those of other accidents and errors ($21914). Simulations estimated that insomnia was associated with 7.2% of all costly workplace accidents and errors and 23.7% of all the costs of these incidents. These proportions are higher than for any other chronic condition, with annualized US population projections of 274 000 costly insomnia-related workplace accidents and errors having a combined value of US $31.1 billion. Conclusion: Effectiveness trials are needed to determine whether expanded screening, outreach, and treatment of workers with insomnia would yield a positive return on investment for employers. Arch Gen Psychiatry. 2012;69(10):1054-1063

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据